Literature DB >> 14562050

Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.

Kazutsugu Uematsu1, Biao He, Liang You, Zhidong Xu, Frank McCormick, David Mark Jablons.   

Abstract

Non small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the United States and worldwide. Unfortunately, standard therapies remain inadequate. An increased understanding of the molecular biology of lung cancer biology is required to develop more effective new therapies. In this report, we show that the Wnt pathway is activated through Dishevelled (Dvl) overexpression in NSCLC. Analysis of freshly resected tumors and lung cancer cell lines demonstrate that Dvl-3, a critical mediator of Wnt signaling, is overexpressed. Specifically, Dvl-3 was overexpressed significantly in 75% of fresh NSCLC microdissected samples compared to control paired matched normal lung samples. To evaluate the biological significance of Wnt signaling and, in particular, Dvl function in lung cancer, we transfected siRNA (designed to inhibit selectively human Dvl-1, -2, and -3), to the NSCLC cell line H1703, which is known to have beta-catenin-mediated Tcf-dependent transcriptional activity. Here, we demonstrate that Dvl-specific siRNA treatment in H1703 decreases significantly Dvl and beta-catenin expression, resulting in reduction of Tcf-dependent transcriptional activity, and, importantly, growth inhibition. Taken together, these data support the novel hypothesis that Dvl overexpression is critical to Wnt signaling activation and cell growth in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14562050     DOI: 10.1038/sj.onc.1206817

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  130 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

2.  Controversies in cancer stem cells: targeting embryonic signaling pathways.

Authors:  Naoko Takebe; S Percy Ivy
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

3.  Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer.

Authors:  Kazumori Kawakami; Soichiro Yamamura; Hiroshi Hirata; Koji Ueno; Sharanjot Saini; Shahana Majid; Yuichiro Tanaka; Ken Kawamoto; Hideki Enokida; Masayuki Nakagawa; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 4.  Development of anticancer agents targeting the Wnt/β-catenin signaling.

Authors:  Xiangqian Zhang; Jijun Hao
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

5.  Activation of p53 by Dishevelled independent of Wnt or planar polarity pathways.

Authors:  Vivianne W Ding; Li-Ping Lin; Andrew L Chiang; Frank McCormick
Journal:  J Mol Med (Berl)       Date:  2007-06-26       Impact factor: 4.599

Review 6.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

Review 7.  The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion.

Authors:  Peter Neth; Christian Ries; Marisa Karow; Virginia Egea; Matthias Ilmer; Marianne Jochum
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 5.739

Review 8.  The way Wnt works: components and mechanism.

Authors:  Kenyi Saito-Diaz; Tony W Chen; Xiaoxi Wang; Curtis A Thorne; Heather A Wallace; Andrea Page-McCaw; Ethan Lee
Journal:  Growth Factors       Date:  2012-12-21       Impact factor: 2.511

Review 9.  Cancer stem cells in lung cancer: Evidence and controversies.

Authors:  Muhammad Alamgeer; Craig D Peacock; William Matsui; Vinod Ganju; D Neil Watkins
Journal:  Respirology       Date:  2013-07       Impact factor: 6.424

10.  Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.

Authors:  Martin Schlensog; Lara Magnus; Timon Heide; Julian Eschenbruch; Florian Steib; Maximilian Tator; Vera Kloten; Michael Rose; Erik Noetzel; Nadine T Gaisa; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2018-04-18       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.